Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2025-11-06 00:00:00 ET · period of report 2025-11-04 · accession 0001882909-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-06 | 2025-11-04 | TVTX | Calvin Sandra | SVP, CAO | M - OptEx | $24.02 | +61.2K | 109.4K | +127% | +$1.47M |
| D | 2025-11-06 | 2025-11-04 | TVTX | Calvin Sandra | SVP, CAO | S - Sale+OE | $36.00 | -67.1K | 48.5K | -58% | -$2.42M |
| DM | 2025-11-06 | 2025-11-04 | TVTX | Calvin Sandra | SVP, CAO | M - OptEx | $0.00 | -61.2K | 18.8K | -77% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-04 | M | A | 6,250 | $8.93 | 115,660 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-04 | S | D | 67,115 | $36.00 | 48,545 | D | — | — | |
| 3 | Common | Common Stock | 2025-11-04 | M | A | 10,000 | $25.25 | 64,410 | D | — | — | |
| 4 | Common | Common Stock | 2025-11-04 | M | A | 17,500 | $26.88 | 81,910 | D | — | — | |
| 5 | Common | Common Stock | 2025-11-04 | M | A | 15,000 | $27.50 | 96,910 | D | — | — | |
| 6 | Common | Common Stock | 2025-11-04 | M | A | 12,500 | $22.40 | 109,410 | D | — | — | |
| 7 | Derivative | Employee stock option (right to buy) | 2025-11-04 | M | D | 12,500 | $0.00 | 7,500 | D | $22.40 · — to 2033-01-31 | 12,500 Common Stock | (F4) One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. |
| 8 | Derivative | Employee stock option (right to buy) | 2025-11-04 | M | D | 15,000 | $0.00 | 2,500 | D | $27.50 · — to 2032-01-31 | 15,000 Common Stock | (F3) One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2022, and the remaining shares vest in 36 equal monthly installments thereafter. |
| 9 | Derivative | Employee stock option (right to buy) | 2025-11-04 | M | D | 17,500 | $0.00 | 0 | D | $26.88 · — to 2031-01-21 | 17,500 Common Stock | (F2) The stock option is fully vested and exercisable. |
| 10 | Derivative | Employee stock option (right to buy) | 2025-11-04 | M | D | 10,000 | $0.00 | 0 | D | $25.25 · — to 2028-05-10 | 10,000 Common Stock | (F2) The stock option is fully vested and exercisable. |
| 11 | Derivative | Employee stock option (right to buy) | 2025-11-04 | M | D | 6,250 | $0.00 | 18,750 | D | $8.93 · — to 2034-01-31 | 6,250 Common Stock | (F5) One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. |